Why the study?
Is long-term left ventricular assist device (LVAD) support cost-effective compared to medical management in patients with advanced heart failure?
Is long-term left ventricular assist device (LVAD) support cost-effective compared to medical management in patients with advanced heart failure?
No takes yet. Share an insight, caveat, or question.
Advancements in continuous flow LVADs and multidisciplinary care have improved survival and quality of life at a cost-effectiveness ratio considered to be of intermediate value.
Rajapreyar et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: